LCRF News: September 2022

Free to Breathe Walks Coming Up Soon! Register Today!

Kansas City - Saturday, Sept 24, 2022 at Heritage Park

Chicago – Saturday, October 22, 2022 at Montrose Harbor

New York - Saturday, October 22, 2022 at Brooklyn Korean War Veterans Plaza

Jersey Shore – Saturday, October 22, 2022 at Asbury Ale House

Anywhere – Saturday, October 22, 2022 in Your Own Community

Give Wings to Research –

#TogetherSeparately Monthly Livestreams & Facebook Group

LCRF hosts webinars to bring the lung cancer community together to discuss topics important to them. Find out more and register for an upcoming livestream. The community also has a lively and engaged Facebook group.

#TogetherSeparately: Women & Lung Cancer

Wednesday, September 21 at 12 pm EDT

Dr. Narjust Florez from Dana-Farber Cancer Institute will join our moderator, Dr. Isabel Preeshagul, for our Lung Cancer Community Talk on Wednesday, September 21 at 12 PM ET. This livestream is an opportunity to connect face-to-face with others who care about lung cancer and talk about challenges we’re facing.

We hope you’ll join us for this important discussion on women and lung cancer – where we’ll communicate risk factors, actionable prevention, and early detection steps to improve outcomes for women, particularly women of color, who are diagnosed with lung cancer. We’ll also address what we need to know and understand about how women uniquely experience lung cancer, and what known differences are seen in lung cancer between men and women.

LCRF updates its Comprehensive Biomarker Testing educational resource, now available for download:

You do not need to be a doctor to understand your tumor. Biomarker testing can help.

When your doctors suspected you had cancer, they took a small portion of your tumor tissue (a biopsy) to have it examined. A specialist, called a pathologist, looked at your tumor cells under the microscope and found out you had lung cancer. There are two main types of lung cancer–small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). If you have NSCLC, the pathologist looks closely at the cancer cells for certain characteristics (features or qualities). Tumors with similar characteristics are referred to as subtypes. Adenocarcinoma (A-deh-noh-KAR-sih-NOH-muh) and squamous cell carcinoma (SKWAY-mus sel KAR-sih-NOH-muh) are the most common subtypes of NSCLC. Once your health care team knows the subtype of your cancer, treatment planning can begin. Read more & download your copy at LCRF.org/biomarkers.

LCRF News:

LCRF announces Education & Engagement Committee

Good News: FDA approves drug for HER-2 unresectable or metastatic NSCLC